Literature DB >> 28300575

Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.

Kossivi Dantey1, Karen Schoedel1, Oleksandr Yergiyev1, David Bartlett2, Uma N M Rao3.   

Abstract

In this study the histologic grade of dedifferentiated liposarcomas was correlated with outcome in surgically resected specimens in 55 patients over a 19-year period at the University of Pittsburgh Medical Center. The tumors were located in the retroperitoneum (N=35); the extremities and thigh (N=16), and the remainder involved the spermatic cord and head and neck. Most tumors were large (mean=21 cm.) Follow-up was available in all 55 patients (median=36 months). Forty-one tumors classified as high-grade dedifferentiated liposarcoma (HG-DDLPS) had mitotically active pleomorphic and spindle cells and foci of necrosis. They included tumors with foci of smooth muscle differentiation (N=12), osteosarcoma (N=4), and myxoid areas (N=9). Fourteen tumors classified as low-grade dedifferentiated liposarcoma (LG-DDLPS) displayed a predominantly bland, monomorphic, spindle cell population with few mitoses and scant necrosis. The Kaplan-Meier method and log-rank test were used for statistical analysis. All tumors had unequivocal foci of well-differentiated liposarcoma (WDLPS). Fluorescence in situ hybridization (FISH) detected amplification of MDM2 in 29 cases. Twenty of 41 patients (49%) with HG-DDLPS died of tumor, and two patients died with LG-DDLPS (14%). The overall survival of patients with LG-DDLPS was significantly longer (P=.02). The median survival was 113 months for the LG-DDLPS and 48 months for the HG-DDLPS. Metastases (N=4) occurred only in the high-grade tumors and were independent of the type of heterologous differentiation. Patients with HG-DDLPS were at a greater risk of earlier death. Distinction between the two groups is important for patient selection for possible adjuvant therapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High-grade dedifferentiated liposarcoma; Histological grade; Low-grade dedifferentiated liposarcoma; MDM2; Myxoid liposarcoma; Survival

Mesh:

Substances:

Year:  2017        PMID: 28300575     DOI: 10.1016/j.humpath.2017.02.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

1.  Primary anatomical site, adjuvant therapy, and other prognostic variables for dedifferentiated liposarcoma.

Authors:  Jonathan Gootee; Sarah Aurit; Christina Curtin; Peter Silberstein
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-25       Impact factor: 4.553

2.  Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis.

Authors:  Kamil M Amer; Dominick V Congiusta; Jennifer E Thomson; Samer Elsamna; Iftikhar Chaudhry; Anthony Bozzo; Rami Amer; Brianna Siracuse; Michelle Ghert; Kathleen S Beebe
Journal:  J Clin Orthop Trauma       Date:  2020-04-18

3.  What Are the Results of Resection of Localized Dedifferentiated Liposarcomas in the Extremities?

Authors:  Eiji Nakata; Toshiyuki Kunisada; Joe Hasei; Ryuichi Nakahara; Hiroyuki Yanai; Tomohiro Toji; Hirofumi Inoue Ct; Toshifumi Ozaki
Journal:  Clin Orthop Relat Res       Date:  2020-11       Impact factor: 4.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.